IONS Q4 2024 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$13B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$227M-30.2% YoY

Gross Profit

$223M98.3% margin

Operating Income

-$111M-48.9% margin

Net Income

-$104M-46.1% margin

EPS (Diluted)

$-0.66

QoQ Revenue Growth

+69.3%

Cash Flow

Operating Cash Flow

-$116M

Free Cash Flow

-$142M

Stock-Based Comp.

$36M

Balance Sheet

Total Assets

$3.0B

Total Liabilities

$2.4B

Stockholders' Equity

$588M

Cash & Equivalents

$242M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$227M	$325M	-30.2%
Gross Profit	$223M	$321M	-30.7%
Operating Income	-$111M	-$6M	-1709.9%
Net Income	-$104M	-$9M	-1026.5%

Revenue Segments

Research and Development Revenue

$201M31%

Collaborative Agreement Revenue

$146M23%

Commercial

$145M23%

SPINRAZA Royalties

$102M16%

Other Commercial

$32M5%

Product

$17M3%